INCYTE CORP
SpecialtyINCYTE CORP is a specialty pharmaceutical company focused on Oncology, Dermatology, Immunology. Key products include JAKAFI.
FDA Novel Drug Designations
(2020-2024)See 3 novel approvals →
INCYTE CORP at a Glance
- Fast trial execution (32 months median completion)
INCYTE CORP's Key Drugs
INCYTE CORP's core commercial portfolio centers on JAKAFI, ZYNYZ, PEMAZYRE, spanning Oncology and Dermatology — its most strategically important drugs approved in the last 15 years.
Myelofibrosis
Squamous Cell Carcinoma of the Anal Canal
Cholangiocarcinoma
Atopic Dermatitis
Chronic Graft-versus-Host Disease
INCYTE CORP's Recent FDA Approvals
INCYTE CORP secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
INCYTE CORP's Therapeutic Areas
INCYTE CORP's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Dermatology, across 0 biologic and 4 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
INCYTE CORP's Top Competitors
INCYTE CORP's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Eli Lilly, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
INCYTE CORP Pipeline Snapshot
INCYTE CORP has 164 active clinical programs from ClinicalTrials.gov — 31 Phase 3, 58 Phase 2 and 75 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 23/58 completed
- • Speed: 32 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges